The UK’s innovative life sciences sector has called on Government to deliver policy continuity, unlock scale-up investment and improve patient access to new medicines.
Driven by world-class science and monumental funding, the UK TechBio sector is undergoing a profound paradigm shift – meet the innovative BIA members leading the charge
Cell and Gene Therapy Catapult (CGT Catapult) will provide investment to Lir Therapeutics (Lir) to accelerate the development of nAAVigator, its AI-driven AAV capsid design platform.
Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline.
Brainomix announces an expansion of its partnership with Boehringer Ingelheim to improve the care of patients with progressive pulmonary fibrosis (PPF).
BIA calls for coordinated action and a clear mandate for Health Data Research Service (HDRS) to prioritise UK value creation with health innovators and job creators, a key sector for economic growth
BIA’s health data vision 2035 report sets out how the UK can use consented and well-governed health data to drive economic growth, innovation and better patient outcomes.
Outpost Bio has raised $3.5 million in pre-seed funding to build frontier AI models that make human microbiology computable, enabling more precise prediction and optimization of intervention outcomes.
With Rare Disease Day coming up next weekend, we at BIA are taking time to reflect on our important advocacy and thought leadership in this space, but also on what we hope to achieve in terms of boosting our influence collectively alongside our Charity Partner of the Year.
It’s been an energising week across the UK life sciences landscape, marked by major investment, important conversations and new opportunities for our community.
Our UK biotech financing 2025 report is out today, including data and commentary on how the biotech investment landscape fared last year. 2025 was a brutal year for the sector, but an upswing in deal numbers going into 2026 and recent capital injections give good reason to be optimistic.
Brainomix, a global leader and pioneer of AI-powered imaging biomarkers for stroke and lung fibrosis, has announced results from its partnership with Argenica Therapeutics for imaging and clinical data analysis of the Phase II trial evaluating ARG-007, a neuroprotective agent for acute ischemic stroke.
Our final blog of 2025 celebrates some excellent fundraising news to close the year, while highlighting key opportunities to engage with and shape the UK life sciences agenda — including the development of UK engineering biology, data policy, a cross-cancer research policy position and salary benchmarking.
This webinar spotlighted the latest capabilities from Our Future Health, the UK’s largest health research programme, now offering imputed and geographic data, dispensed medication records, and direct participant recruitment pathways.
Scancell Holdings, the developer of active immunotherapies to treat cancer, announces updated positive data from the SCOPE Phase 2 trial of iSCIB1+ in combination with ipilimumab and nivolumab, current standard of care (SoC).
